Developed and launched by Mirus, the flagship product TransIT-X2® Transfection Reagent integrates multifunctionality with high performance, demonstrating efficient compatibility with both broad-spectrum and hard-to-transfect cell lines. It effectively circumvents tedious condition optimization and repetitive experimentation, significantly enhancing experimental efficiency and result reliability.

Novel Technology: Advanced LPNC Complex Patent Formulation

Mirus has abandoned traditional single-component models and relies on patented polymer/lipid multidimensional hybridization technology. Within a non-liposomal nano-structured system, it constructs diversified transfection strategies that effectively overcome multiple intracellular delivery barriers, markedly improving transfection efficiency while substantially reducing cytotoxicity.

TransIT-X2® Features a Highly Efficient Workflow

TransIT-X2® requires no complex pretreatment, significantly shortening the duration of transfection procedures. From complex preparation to sample loading, the entire process is rapid, greatly improving experimental throughput.

Product Advantages of TransIT-X2®

Broad-Spectrum High Efficiency

TransIT-X2® exhibits exceptional broad-spectrum transfection efficiency. In comparative experiments across 41 cell lines, it achieved luciferase expression superior to or equivalent to common liposomal transfection reagents in 36 cell lines; among these, expression levels in 17 cell lines were more than twice as high as those obtained with common liposomal transfection reagents.

Very Low Cytotoxicity

The dynamic delivery system of TransIT-X2® outperforms common liposomal transfection reagents. In A549 and MDCK cells transfected with a luciferase plasmid for 24 hours using either TransIT-X2® or common liposomal transfection reagents, transfection efficiency was assessed via luciferase activity assays and cytotoxicity was evaluated using LDH release assays. Results indicate that, under optimal ratios, TransIT-X2® significantly enhances exogenous gene expression while reducing cytotoxicity compared with common liposomal transfection reagents.

Wide Compatibility

Ordering Information

Company Profiles

Founded in 1995, Mirus Bio is one of the earliest companies worldwide dedicated to the development of highly efficient, low-toxicity transfection reagents, and remains a leading supplier in this field. Mirus is recognized as a pioneer in transfection technology, having earned extensive international acclaim and long-term trust from the scientific community through multiple groundbreaking achievements.

XMJ Scientific serves as the China Regional Agent for Mirus. Upholding professionalism and rigorous standards, XMJ is committed to providing customers with premium products and services. For inquiries regarding the aforementioned products, please contact the XMJ customer service hotline at 400-050-4006 or visit the website www.lxhmstone.com  for more information.